School of Medicine


Showing 21-34 of 34 Results

  • Sydney X. Lu

    Sydney X. Lu

    Assistant Professor of Medicine (Hematology)

    BioSydney Lu is an assistant professor and physician-scientist in the Division of Hematology, Department of Medicine with a broad interest in both normal and abnormal RNA processing in the context of normal physiology and disease states. The laboratory studies translational questions regarding the mechanistic basis of RNA processing abnormalities in malignant blood disorders, their implications for leukemogenesis and cancer biology, as well as resultant therapeutic opportunities.

    As a physician, Sydney’s group is particularly focused on dissecting RNA processing abnormalities in primary patient samples and disease-relevant preclinical model systems. Lab members employ a variety of ‘wet-lab’ and computational approaches to study transcriptome abnormalities in (1) states of immune dysfunction, (2) myeloid blood cancers such as myelodysplastic syndromes and acute myeloid leukemia, and (3) lymphoid blood cancers such as chronic lymphocytic leukemia. Additional projects are focused on novel therapeutics, including multiple targeted agents which modulate RNA processing, for the selective treatment of these diseases.

    Sydney’s research is/has been supposed by grant funding from the National Cancer Institute, Parker Institute for Cancer Immunotherapy, Leukemia & Lymphoma Society, Aplastic Anemia & Myelodysplastic Syndromes International Foundation, the American Society for Clinical Oncology, the American Society of Hematology, the American Association for Cancer Research, the Paula and Rodger Riney Foundation, the Doris Duke Charitable Foundation, The Gabrielles Angel Foundation for Cancer Research, and the Stanford Cancer Institute.

  • Gabriel Mannis

    Gabriel Mannis

    Associate Professor of Medicine (Hematology)

    Current Research and Scholarly InterestsMy research focuses on the development of more effective, less toxic therapies for patients with AML and other high-risk hematologic malignancies. We study biologic correlates that predict response to therapy as well as factors/interventions that improve quality-of-life for patients struggling with blood-borne cancers.

  • Bruno Medeiros

    Bruno Medeiros

    Adjunct Clinical Associate Professor, Medicine - Hematology

    Current Research and Scholarly InterestsMy clinical activities combine the development of novel therapeutic modalities, translational research activities and epidemiological study of acute leukemia. My special focus is on the development of better, patient tailored therapies for young and elderly patients with acute leukemia.

  • Ann Mullally

    Ann Mullally

    Professor of Medicine (Hematology)

    Current Research and Scholarly InterestsDr. Ann Mullally's aboratory studies the genetics, biology and therapy of myeloid blood cancers, with a focus on myeloproliferative neoplasms (MPN). Using primary human samples, mouse models, genomics, single-cell sequencing and CRISPR, as well as cellular and molecular biology, the lab has investigated the key genetic events underlying MPN pathogenesis. Dr. Mullally’s lab elucidated the mechanism by which mutant calreticulin (CALR) is oncogenic and causes MPN.

  • Giselle (Ghazal) Salmasi, MD

    Giselle (Ghazal) Salmasi, MD

    Clinical Associate Professor, Medicine - Hematology

    BioDr. Salmasi is a board-certified, fellowship-trained hematologist. She treats patients in the Hematology Program and the Hematologic Cancer Program at Stanford Health Care. Dr. Salmasi is the associate clinical chief for classical hematology. She is also a clinical associate professor in the Division of Hematology, Department of Medicine at Stanford University School of Medicine.

    She treats a wide range of blood disorders and blood cancers. Her clinical/research interests include immune thrombocytopenia (ITP) and warm autoimmune hemolytic anemia (wAIHA). Dr. Salmasi understands that patients need social and emotional support along with medical care. She founded the earliest adolescent and young adult survivorship support groups in Santa Cruz, California, and Toronto, Canada. Dr. Salmasi is also dedicated to training future doctors in providing excellent hematologic care.

    Dr. Salmasi was the medical co-investigator for a national phase 3 clinical trial of endovascular therapy for treating chronic venous thrombosis.

    Her research has appeared in the New England Journal of Medicine, Leukemia & Lymphoma journal and the Transfusion and Apheresis Science journal. Dr. Salmasi’s publications include articles and a chapter about lymphoma. She has also reviewed articles for the Biology of Blood and Marrow Transplantation journal and the Journal of Clinical Oncology.

    Dr. Salmasi is a member of the American Society of Hematology.

  • William Shomali

    William Shomali

    Clinical Assistant Professor, Medicine - Hematology

    BioDr. Shomali is a clinical assistant professor of Hematology at Stanford University School of Medicine. He is board certified in hematology & medical oncology.

    Dr. Shomali specializes in the treatment of blood cancers such as myeloproliferative neoplasms and myelodysplastic syndromes. He aims to provide compassionate, personalized, and evidence-based care to each patient.

    Dr. Shomali received his medical degree from the University of Jordan, followed by a postdoctoral fellowship at MD Anderson Cancer Center where he studied infections in cancer patients and the role of biomarkers in defining tumor fever. He completed his residency training in Internal Medicine at the Cleveland Clinic Foundation where he served as a Chief Medical Resident. He then joined Stanford University for his combined Hematology & Oncology fellowship training.

    Dr. Shomali’s research interests include the study of novel agents in myeloproliferative neoplasms and myelodysplastic syndromes. He developed investigator-initiated clinical trials for patients with eosinophilic neoplasms and advanced myelofibrosis. In addition, he co-authored several papers and book chapters discussing the care of patients with cancer. His work has been presented in national meetings and published in peer reviewed journals including Blood, American Journal of Hematology, British Journal of Hematology, Leukemia & Lymphoma, and Cancer.

    Among his honors, Dr. Shomali received the Cleveland Clinic Excellence in Teaching Award and was named to the Alpha Omega Alpha Medical Honor Society. He has received a Young Investigator Award from the Conquer Cancer Foundation, an NIH Institutional National Research Service Award, and a Stanford Cancer Institute Fellowship Award.

    Dr. Shomali is a member of the American Society of Hematology and the American Society of Clinical Oncology.

  • James L. Zehnder, M.D.

    James L. Zehnder, M.D.

    Professor of Pathology (Research) and of Medicine (Hematology)

    Current Research and Scholarly InterestsMy main research and clinical interests include molecular pathogenesis of acquired cytopenias, genetic testing for inherited non-malignant hematologic disorders, next-generation sequencing approaches to T and B cell clonality testing, somatic mutations in cancer and assessment of minimal residual disease in cancer patients.

  • Tian Yi Zhang, MD, PhD

    Tian Yi Zhang, MD, PhD

    Assistant Professor of Medicine (Hematology)

    BioDr. Zhang is a board-certified hematologist. She is also an assistant professor of hematology at Stanford University School of Medicine. In addition to her medical degree, she holds a PhD in cellular and molecular immunology.

    In her clinical practice, she treats patients with all forms of hematological malignancies, offering specialized expertise in acute myeloid leukemia, including therapy-resistant cases. For each patient, she develops a personalized care plan encompassing novel treatment options.

    Her research activities include conducting early phase clinical trials, investigator initiated clinical trials (IITs), studying the immune repertoire in patients with myeloid malignancies, and exploring cholesterol metabolic dependencies of acute myeloid leukemia (AML).

    She was the recipient of an A.P. Giannini Foundation fellowship award, which supports innovative research. The award helped fund Dr. Zhang’s study of how AML cells interact with other cells in bone marrow. A significant finding confirmed that AML cells secrete a protein that suppresses the production of red blood cells, the same protein that causes inflammation in disorders such as rheumatoid arthritis and Crohn’s disease.

    Her many other honors include the National Cancer Institute Career Development (K08) Award, the American Society of Hematology (ASH) Research Training Award for Fellows, Stanford Cancer Institute - American Cancer Society (SCI-ACS) Pilot Grant and Best ASH Abstract Award two years in a row. She also has earned recognition from the National Institutes of Health and American College of Physicians.

    She has published her research findings on topics such as advanced therapy for high-risk myelodysplastic syndromes and reversal of bone marrow failure induced by AML. Her work has appeared in Leukemia & Lymphoma, Science Translational Medicine, Cancer Research, the Journal of Clinical Investigation, Journal of Immunology, and elsewhere.

    Dr. Zhang is a member of the American Association of Cancer Research and American Society of Hematology. She advises and mentors Stanford medical students, residents and fellows. She delivers invited lectures to faculty and fellows. In addition, she has been an invited speaker on the topic of acute myeloid leukemia at the Association of Northern California Oncologists Update on Hematological Malignancies.